Gilead Sciences (GILD) Stock Forecast & Price Target

Compare

13,497 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GILD Analyst Ratings

Strong Buy

19 Buy

6 Hold

0 Sell

Based on 25 analysts giving stock ratings to

Gilead

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GILD Stock 12 Month Forecast

Average Price Target

$125.30

▲(7.89% Upside)

Based on 25 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $125.30 with a high forecast of $143.00 and a low forecast of $98.00. The average price target represents a 7.89% change from the last price of $116.14.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"73":"$73","144":"$144","90.75":"$90.8","108.5":"$108.5","126.25":"$126.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$143.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$125.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":98,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$98.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[73,90.75,108.5,126.25,144],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.18,115.47384615384615,117.76769230769231,120.06153846153846,122.35538461538462,124.64923076923077,126.94307692307693,129.2369230769231,131.53076923076924,133.82461538461538,136.11846153846153,138.4123076923077,140.70615384615385,{"y":143,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.18,114.1123076923077,115.04461538461538,115.97692307692309,116.90923076923077,117.84153846153846,118.77384615384615,119.70615384615385,120.63846153846154,121.57076923076923,122.50307692307692,123.43538461538462,124.36769230769231,{"y":125.3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.18,112.0123076923077,110.8446153846154,109.67692307692309,108.50923076923077,107.34153846153846,106.17384615384616,105.00615384615385,103.83846153846154,102.67076923076924,101.50307692307692,100.33538461538461,99.1676923076923,{"y":98,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":74.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.53,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.08,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.93,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.84,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 72,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$143.00

Average Price Target$125.30

Lowest Price Target$98.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Evan Seigerman

BMO Capital

$130

Buy

11.93%

Upside

Reiterated

08/21/25

Gilead Sciences (GILD) Receives a Buy from BMO CapitalBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $130.00 price target on Gilead Sciences (NASDAQ: GILD).

Courtney Breen

Bernstein

$120→$135

Buy

16.24%

Upside

Reiterated

08/19/25

Gilead Sciences: Strong Market Position and Investor Confidence Justify Buy Rating

Narumi Nakagiri

Daiwa

$128

Buy

10.21%

Upside

Upgraded

08/18/25

Gilead upgraded to Outperform from Neutral at DaiwaGilead upgraded to Outperform from Neutral at Daiwa

Salim Syed

Mizuho Securities

$117→$131

Buy

12.79%

Upside

Reiterated

08/18/25

Gilead Sciences (GILD) Gets a Buy from Mizuho SecuritiesMizuho analyst Salim Syed raised the price target on Gilead Sciences (NASDAQ: GILD) to $131.00 (from $117.00) while maintaining a Outperform rating.

Veda Pharmyne

TR | OpenAI - 4o

$134→$131

Hold

12.79%

Upside

Downgraded

08/14/25

AI Generated ArticleAI Generated Article

Carter Gould

Cantor Fitzgerald

$129

Buy

11.07%

Upside

Reiterated

08/13/25

Cantor Fitzgerald Keeps Their Buy Rating on Gilead Sciences (GILD)Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $129.00 price target on Gilead Sciences (NASDAQ: GILD).

Michael Okunewitch

Maxim Group

―

Hold

―

Reiterated

08/13/25

Gilead Sciences: Hold Rating Amidst Strong HIV Performance and Limited Growth Prospects

James Shin

Deutsche Bank

$120→$135

Buy

16.24%

Upside

Reiterated

08/11/25

Gilead price target raised to $135 from $120 at Deutsche BankGilead price target raised to $135 from $120 at Deutsche Bank

Joseph Stringer

Needham

$133

Buy

14.52%

Upside

Reiterated

08/08/25

Gilead Sciences: Strong Q2 Performance and Promising Outlook Drive Buy Rating

Tim Anderson

Bank of America Securities

$126→$140

Buy

20.54%

Upside

Reiterated

08/08/25

Gilead price target raised to $140 from $126 at BofAGilead price target raised to $140 from $126 at BofA

Terence Flynn

Morgan Stanley

$135→$143

Buy

23.13%

Upside

Reiterated

08/08/25

Morgan Stanley Sticks to Its Buy Rating for Gilead Sciences (GILD)

Geoff Meacham

Citi

$125

Buy

7.63%

Upside

Reiterated

08/08/25

Gilead Sciences (GILD) Receives a Buy from Citi

Chris Schott

J.P. Morgan

$130→$135

Buy

16.24%

Upside

Reiterated

08/08/25

Gilead Sciences (GILD) Receives a Buy from J.P. MorganJPMorgan analyst Chris Schott raised the price target on Gilead Sciences (NASDAQ: GILD) to $135.00 (from $130.00) while maintaining a Overweight rating.

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

08/08/25

Analysts Offer Insights on Healthcare Companies: Omada Health, Inc. (NASDAQ: OMDA), Gilead Sciences (NASDAQ: GILD) and Cytokinetics (NASDAQ: CYTK)

Tyler Van Buren

TD Cowen

$110→$115

Buy

-0.98%

Downside

Reiterated

08/08/25

Gilead Sciences: Strong Financial Performance and Positive Outlook Justify Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Evan Seigerman

BMO Capital

$130

Buy

11.93%

Upside

Reiterated

08/21/25

Gilead Sciences (GILD) Receives a Buy from BMO CapitalBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $130.00 price target on Gilead Sciences (NASDAQ: GILD).

Courtney Breen

Bernstein

$120→$135

Buy

16.24%

Upside

Reiterated

08/19/25

Gilead Sciences: Strong Market Position and Investor Confidence Justify Buy Rating

Narumi Nakagiri

Daiwa

$128

Buy

10.21%

Upside

Upgraded

08/18/25

Gilead upgraded to Outperform from Neutral at DaiwaGilead upgraded to Outperform from Neutral at Daiwa

Salim Syed

Mizuho Securities

$117→$131

Buy

12.79%

Upside

Reiterated

08/18/25

Veda Pharmyne

TR | OpenAI - 4o

$134→$131

Hold

12.79%

Upside

Downgraded

08/14/25

AI Generated ArticleAI Generated Article

Carter Gould

Cantor Fitzgerald

$129

Buy

11.07%

Upside

Reiterated

08/13/25

Cantor Fitzgerald Keeps Their Buy Rating on Gilead Sciences (GILD)Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $129.00 price target on Gilead Sciences (NASDAQ: GILD).

Michael Okunewitch

Maxim Group

―

Hold

―

Reiterated

08/13/25

Gilead Sciences: Hold Rating Amidst Strong HIV Performance and Limited Growth Prospects

James Shin

Deutsche Bank

$120→$135

Buy

16.24%

Upside

Reiterated

08/11/25

Gilead price target raised to $135 from $120 at Deutsche BankGilead price target raised to $135 from $120 at Deutsche Bank

Joseph Stringer

Needham

$133

Buy

14.52%

Upside

Reiterated

08/08/25

Gilead Sciences: Strong Q2 Performance and Promising Outlook Drive Buy Rating

Tim Anderson

Bank of America Securities

$126→$140

Buy

20.54%

Upside

Reiterated

08/08/25

Gilead price target raised to $140 from $126 at BofAGilead price target raised to $140 from $126 at BofA

Terence Flynn

Morgan Stanley

$135→$143

Buy

23.13%

Upside

Reiterated

08/08/25

Morgan Stanley Sticks to Its Buy Rating for Gilead Sciences (GILD)

Geoff Meacham

Citi

$125

Buy

7.63%

Upside

Reiterated

08/08/25

Gilead Sciences (GILD) Receives a Buy from Citi

Chris Schott

J.P. Morgan

$130→$135

Buy

16.24%

Upside

Reiterated

08/08/25

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

08/08/25

Analysts Offer Insights on Healthcare Companies: Omada Health, Inc. (NASDAQ: OMDA), Gilead Sciences (NASDAQ: GILD) and Cytokinetics (NASDAQ: CYTK)

Tyler Van Buren

TD Cowen

$110→$115

Buy

-0.98%

Downside

Reiterated

08/08/25

Gilead Sciences: Strong Financial Performance and Positive Outlook Justify Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

1 Month

xxx

Success Rate

21/32 ratings generated profit

Average Return

+2.93%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.63% of your transactions generating a profit, with an average return of +2.93% per trade.

3 Months

xxx

Success Rate

22/32 ratings generated profit

Average Return

+3.82%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +3.82% per trade.

1 Year

Mohit BansalWells Fargo

Success Rate

16/18 ratings generated profit

Average Return

+11.83%

reiterated a buy rating 16 days ago

Copying Mohit Bansal's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +11.83% per trade.

2 Years

xxx

Success Rate

15/15 ratings generated profit

Average Return

+54.15%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +54.15% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GILD Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GILD has received 64 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. GILD average Analyst price target in the past 3 months is 125.30.

Each month's total comprises the sum of three months' worth of ratings.

GILD Financial Forecast

GILD Earnings Forecast

Next quarter’s earnings estimate for GILD is $2.16 with a range of $2.04 to $2.37. The previous quarter’s EPS was $2.01. GILD beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.06% of the time in the same period. In the last calendar year GILD has Outperformed its overall industry.

GILD Sales Forecast

Next quarter’s sales forecast for GILD is $7.41B with a range of $7.22B to $7.82B. The previous quarter’s sales results were $7.06B. GILD beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.27% of the time in the same period. In the last calendar year GILD has Outperformed its overall industry.

GILD Stock Forecast FAQ

What is GILD’s average 12-month price target, according to analysts?

Based on analyst ratings, Gilead Sciences’s 12-month average price target is 125.30.

What is GILD’s upside potential, based on the analysts’ average price target?

Gilead Sciences has 7.89% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GILD a Buy, Sell or Hold?

Gilead Sciences has a consensus rating of Strong Buy which is based on 19 buy ratings, 6 hold ratings and 0 sell ratings.

What is Gilead Sciences’s price target?

The average price target for Gilead Sciences is 125.30. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $143.00 ,the lowest forecast is $98.00. The average price target represents 7.89% Increase from the current price of $116.14.

What do analysts say about Gilead Sciences?

Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Streets Analysts.

How can I buy shares of GILD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Gilead Sciences (GILD) Stock Forecast & Price Target

GILD Analyst Ratings

GILD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Gilead Sciences

GILD Analyst Recommendation Trends

GILD Financial Forecast

GILD Earnings Forecast

GILD Sales Forecast

GILD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts